Now, our phosphoproteomic study profiling human circulating EVs confirms the activation of CDK1 and PKCδ in humans with prediabetes and diabetes and suggests clinical utility for phosphoproteomics of circulating EVs. This evidence concerns the gene CDK1 and diabetes mellitus.